Risks and Implications of Interrupting Maintenance Psychotropic Drug Therapy
The DOI matches its Crossref record.
Abstract
Editorials| February 18 2010 Risks and Implications of Interrupting Maintenance Psychotropic Drug Therapy Subject Area: Psychiatry and Psychology Ross J. Baldessarini Ross J. Baldessarini Harvard Medical School, Boston, Mass., and Laboratories for Psychiatric Research, and Bipolar and Psychotic Disorders Program, Mailman Research Center and McLean Division of Massachusetts General Hospital, Belmont, Mass., USA Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1995) 63 (3-4): 137–141. https://doi.org/10.1159/000288950 Article history Published Online: February 18 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Ross J. Baldessarini; Risks and Implications of Interrupting Maintenance Psychotropic Drug Therapy. Psychother Psychosom 31 December 1995; 63 (3-4): 137–141. https://doi.org/10.1159/000288950 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 1995Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tapering does not appear to affect the occurrence of withdrawal reactions with antidepressant drugs [39,40] and persistent postwithdrawal disorders months after discontinuation may occur [41].”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [39]
Citations
Cites
Still being checked.
Cited by
Prevention of Recurrent Depression With Cognitive Behavioral Therapy: Preliminary Findings
Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.816 · Cited by 491
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“As Baldessarini (1995) remarks, the assumption that such physiological processes will readjust after a withdrawal phase is not supported by current awareness in the field of drug dependence.”
Continuation and Maintenance Use of Antidepressants in Recurrent Depression
Bockting, C. L. H., ten Doesschate, M. C., Spijker, J., Spinhoven, P., Koeter, M. W. J., & Schene, A. H. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000110056 · Cited by 121
The Road to Recovery from Depression – Don’t Drive Today with Yesterday’s Map
Fava, G. A., Tomba, E., & Grandi, S. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000104701 · Cited by 110
Raising Questions about Antidepressants
Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R., & Gordon, J. S. (1999) · Psychotherapy and Psychosomatics · doi:10.1159/000012304 · Cited by 110
Phantom Tooth Pain: A New Look at an Old Dilemma
Marbach, J. J., & Raphael, K. G. (2000) · Pain Medicine · doi:10.1046/j.1526-4637.2000.00012.x · Cited by 86
Are Antidepressants Overrated? A Review of Methodological Problems in Antidepressant Trials
Moncrieff, J. (2001) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200105000-00003 · Cited by 97
Iatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82
A Risk-Benefit Assessment of Sulpiride in the Treatment of Schizophrenia
Mauri, M. C., Bravin, S., Bitetto, A., Rudelli, R., & INVERNIZZI, G. (1996) · Drug Safety · doi:10.2165/00002018-199614050-00003 · Cited by 74
Long-Term Treatment with Antidepressant Drugs: The Spectacular Achievements of Propaganda
Fava, G. A. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000056279 · Cited by 66
(2008) · Choice Reviews Online · doi:10.5860/choice.45-4410 · Cited by 56
Antidepressants: A triumph of marketing over science?
Antonuccio, D. O., Burns, D. D., & Danton, W. G. (2002) · Prevention & Treatment · doi:10.1037/1522-3736.5.1.525c · Cited by 62
Roman, M. W. (2012) · Issues in Mental Health Nursing · doi:10.3109/01612840.2012.713447 · Cited by 36
Bibliotherapy as a Treatment for Depression in Primary Care
Naylor, E. V., Antonuccio, D. O., Litt, M., Johnson, G. E., Spogen, D. R., Williams, R., McCarthy, C., Lu, M. M., Fiore, D. C., & Higgins, D. L. (2010) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-010-9207-2 · Cited by 43
“... (though not yet established causal relationship) of antidepressants with breast cancer (e.g., Bahl, Cotterchio, & Kreiger, 2003; Cotterchio, Kreiger, Darlington, & Steingart, 2000; Halbreich, Shen, & Panaro, 1996; Moorman, Grubber, Millikan, & Newman, 2003; Sharpe, Collet, Belzile, Hanley, & Boivin, 2002), and the…”
BackgroundTsai, A. C., Rosenlicht, N. Z., Jureidini, J. N., Parry, P. I., Spielmans, G. I., & Healy, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000434 · Cited by 43
Maintenance therapies for classic and other forms of bipolar disorder
Bowden, C. L., Lecrubier, Y., Bauer, M. S., Goodwin, G. M., Greil, W., Sachs, G. S., & von Knorring, L. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00179-8 · Cited by 45
Clinical impact of a 2-week psychotropic medication washout in unipolar depressed inpatients
Grunebaum, M. F., Oquendo, M. A., Burke, A. K., Ellis, S. P., Echavarria, G., Brodsky, B. S., Malone, K. M., & Mann, J. J. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00168-4 · Cited by 26
Potential Sensitising Effects of Antidepressant Drugs on Depression
Fava, G. A. (1999) · CNS Drugs · doi:10.2165/00023210-199912040-00001 · Cited by 23
Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity
Bauer, R., Glenn, T., Alda, M., Sagduyu, K., Marsh, W., Grof, P., MUNOZ, R. A., Murray, G., Ritter, P. S., Lewitzka, U., et al. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-26 · Cited by 17
Glass, K. C., & Waring, D. R. (2005) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2005.tb00520.x · Cited by 16
APA Working Group on Psychoactive Medications for Children and Adolescents (2006) · PsycEXTRA Dataset · doi:10.1037/e539722009-001 · Cited by 14
Relabeling the Medications We Call Antidepressants
Antonuccio, D. O., & Healy, D. T. (2012) · Scientifica · doi:10.6064/2012/965908 · Cited by 16
Screening and Diagnosis of Depression: Are Criteria Followed?
Fava, G. A. (1997) · Disease Management & Health Outcomes · doi:10.2165/00115677-199702010-00001 · Cited by 11
Cognitive-Behavioral Treatment of Depression, Part X: Reducing the Risk of Relapse
Overholser, J. C. (1998) · Journal of Contemporary Psychotherapy · doi:10.1023/a:1022970527103 · Cited by 9
The use of antidepressant drugs: some reasons for concern
Fava, G. A., & Tomba, E. (1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-155 · Cited by 5
De (in)effectiviteit van psychofarmaca
van den Burg, W. (1998) · Directieve therapie · doi:10.1007/bf03060189 · Cited by 5
The Clinical Meaning of Withdrawal with Antidepressant Drugs
Fava, G. A. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000540033 · Cited by 4
Psychosomatic medicine:alive and well in the new century
Fava, G. A., Fabbri, S., Belaise, C., & Tossani, E. (2002) · Revista Portuguesa de Psicossomática · Cited by 4
The End Product: Clinical Practice Guidelines
Whitaker, R., & Cosgrove, L. (2015) · Palgrave Macmillan US eBooks · doi:10.1057/9781137516022_8
Antonuccio, D. O., & Higgins, D. J. (2010)
Metadata
- Authors
- Baldessarini, R. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Baldessarini, Ross J.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2010-02-18
- Volume
- 63
- Issue
- 3-4
- Pages
- 137-141
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2061855555
- Cited by
- 30
- References
- 0
- Citations by year
- 2024: 1 · 2019: 1 · 2015: 1 · 2013: 1 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k05mh047370-25)
- National Institute of Mental Health (P01MH031154, MH-31154, MH47370)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- drug discontinuation, bipolar disorder, relapse, lithium, mood stabilizers, antipsychotic drugs, antiepileptic drugs, lithium withdrawal, antipsychotic withdrawal, anticonvulsant withdrawal
- MeSH terms
- Mental Disorders, Humans, Long-Term Care, Psychotropic Drugs, Recurrence, Risk Factors, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.